| Ticker | AFMD |
|---|---|
| ISIN | NL0015001ZQ0 |
| Sector | Atención sanitaria |
| Mercado | NASDAQ |
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16...
Affimed N.V. opera en el sector Healthcare, industria Biotechnology.